Quantcast
Last updated on April 18, 2014 at 6:54 EDT

Latest Erythropoietin Stories

2010-06-29 06:30:00

NES-ZIONA, Israel, June 29 /PRNewswire-FirstCall/ -- PROLOR Biotech, Inc. (NYSE Amex: PBTH), a company developing next generation biobetter therapeutic proteins, today announced that it has received formal Good Manufacturing Practice (GMP) certification for hGH-CTP, the company's proprietary biobetter version of human growth hormone. GMP certification is required by the European Union (EU) clinical trials legislation as a precondition for conducting clinical trials in EU member countries....

2010-06-22 10:56:00

HARRISBURG, Pa., June 22 /PRNewswire-USNewswire/ -- The Pennsylvania Horse Racing Commission will begin testing thoroughbred race horses for total carbon dioxide, or TCO2, after approving a policy to conduct the testing at its meeting on June 17. The commission first voted to implement TCO2 testing during its March meeting. Since that time, commission staff worked to develop the policy, which strictly prohibits the use of agents or substances that elevate a horse's TCO2 level beyond what...

2010-06-01 06:30:00

NES-ZIONA, Israel, June 1 /PRNewswire-FirstCall/ -- PROLOR Biotech, Inc. (NYSE Amex: PBTH), a clinical stage company developing next generation biobetter therapeutic proteins, today announced that Chief Executive Officer Avri Havron and President Shai Novik will ring the opening bell at the New York Stock Exchange (NYSE) at 9:30 AM ET on Thursday, June 3, 2010. "It is a privilege to celebrate PROLOR's recent listing on the NYSE Amex by ringing the opening bell at the New York Stock...

2010-05-03 06:30:00

NES-ZIONA, Israel, May 3 /PRNewswire-FirstCall/ -- PROLOR Biotech, Inc. (NYSE Amex: PBTH), a company developing next generation biobetter therapeutic proteins, today reported new preclinical data on the company's pipeline of drug candidates designed to reduce the dosing frequency of therapeutic proteins and peptides. The data will be discussed by PROLOR's management at the 2010 BIO International Convention in Chicago, as well as at the upcoming Rodman & Renshaw 6th Annual Global...

2010-04-27 07:00:00

EXTON, Pa., April 27 /PRNewswire/ -- BioTrends Research Group, Inc. is pleased to announce the recent release of two syndicated reports focused on the management of renal anemia in the US. ChartTrends(®): Renal Anemia is an annual publication based on patient and laboratory data collected from over 1,000 dialysis patient charts. It provides significant insight into the factors that drive decisions to treat, brand selection, dose and dose changes and switching behavior....

2010-04-15 07:30:00

NEW YORK, April 15 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) today reported updated long-term efficacy and safety data on Zerenex(TM) (ferric citrate), the Company's iron-based phosphate binder for the treatment of hyperphosphatemia (elevated phosphate levels) from an open-label extension study in patients with end-stage renal disease (ESRD) who are on dialysis. This data was presented yesterday at the National Kidney Foundation (NKF) 2010 Spring Clinical...

2010-04-13 07:30:00

NEW YORK, April 13 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) today announced that several posters on Zerenex(TM) (ferric citrate), the Company's iron-based phosphate binder for the treatment of hyperphosphatemia (elevated phosphate levels) in patients with end-stage renal disease who are on dialysis, have been accepted for presentation at the National Kidney Foundation (NKF) 2010 Spring Clinical Meeting taking place April 13-17, 2010, in Orlando, Florida....

2010-04-12 07:00:00

NES-ZIONA, Israel, April 12 /PRNewswire-FirstCall/ -- PROLOR Biotech, Inc. (NYSE Amex: PBTH), a company developing next generation biobetter therapeutic proteins, today announced that the Israeli Office of the Chief Scientist ("OCS") has approved a 2010 continuation of its grant to PROLOR's Israeli-based R&D subsidiary for the company's development program for hGH-CTP, its proprietary longer-acting version of human growth hormone (hGH). Human growth hormone is indicated for the...

2010-03-25 07:00:00

NES-ZIONA, Israel, March 25 /PRNewswire-FirstCall/ -- PROLOR Biotech, Inc., (OTC Bulletin Board: PBTH), a company developing next generation biobetter therapeutic proteins, today announced that it has been authorized to list its shares of common stock on the NYSE AMEX stock exchange. The company anticipates that its common stock will begin trading on the NYSE AMEX on Monday, March 29, 2010, under the trading symbol "PBTH." Until that time, PROLOR's common stock will continue to trade on...

2010-03-18 07:00:00

NES-ZIONA, Israel, March 18 /PRNewswire-FirstCall/ -- PROLOR Biotech, Inc., (OTC Bulletin Board: PBTH), a company developing next generation biobetter therapeutic proteins, today announced that it has raised $24.4 million in a private placement of 10,382,975 shares of its common stock, par value $0.00001 per share, to accredited investors at a price of $2.35 per share, which represents an approximate 17% discount to the average closing price of the common stock for the 30-day period prior...